LG – Lead Generation
LO – Lead Optimization
P1 – Phase 1
P2 – Phase 2
AMR - ANTIBACTERIAL
BWC0977
IV + Oral step down small molecule agent for treating critical care infections
GYROX-2
Oral small molecule agent for treating community infections
Coverage:
- Critical priority pathogens including carbapenem resistant Enterobacteriaceae, Acinetobacter baumannii & Pseudomonas aeruginosa
- High priority pathogens including Enterococcus faecium, Staphylococcus aureus, Campylobacter sp., Streptococcus pneumoniae
- Bio-threat pathogens including Bacillus anthracis, Yersinia pestis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei
IMMUNO-ONCOLOGY
DARE-1
Small molecule oral immuno-oncologic agents for treating multiple cancers
Coverage:
- Adenosine pathway Implied in CRC, NSCLC, TNBC, PANCREAS, PROSTATE, RCC, HNSCC
- No FDA approved small molecule drug yet
- Available immuno-oncology drugs are biologics presenting with huge cost and toxicity liabilities
- Has a potential for combination with approved immune checkpoint drugs, cytotoxics and targeted therapies
TMET
(Tumour Micro Environment Targets)
Coverage:
- Hypoxia Modulators
- Next-generation checkpoint inhibitors
- Novel kinase inhibitors
Partners
